Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 25 mg - 52 EUR
  • 100 mg - 156 EUR
  • 250 mg - 312 EUR

Axitinib

Axitinib is a potent and selective oral inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. It inhibits cellular autophosphorylation of VEGF receptors (VEGFR) with picomolar IC50 values. Counterscreening across multiple kinase and protein panels showed that it is selective for VEGFRs. Axitinib blocks VEGF-mediated endothelial cell survival, tube formation, and downstream signaling through endothelial nitric oxide synthase, Akt and extracellular signal-regulated kinase. It was approved for use in patients with renal cell carcinoma that had failed to respond to a previous treatment.

catalogue number: A013
synonyms: AG-013736, Inlyta
CAS: 319460-85-0
MW: 386.47 g/mol

References
Clin Cancer Res. 2008 Nov 15;14(22):7272-83. PMID: 19010843
Curr Oncol Rep. 2011 Apr;13(2):103-11. PMID:21318618